GB Sciences is a biotech company developing prescription drugs derived from cannabis compounds, targeting conditions like Parkinson's disease, chronic pain, and depression. Its drug candidates are still in pre-clinical animal testing stages, meaning they are y
The company currently generates no revenue and reports net losses of approximately USD 0.00B per quarter, with negative operating margins around -68%. It relies entirely on external funding to sustain operations, as it has no commercial products or income stre
GB Sciences' potential moat rests on its intellectual property portfolio for cannabinoid-based therapies, but this is weak because the company has no approved drugs, no clinical-stage data, and faces intense competition from larger, better-funded biotech firms
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
